Join us this March for the first ever CURE Patient-Focused Sessions, taking place at the Miami Breast Cancer Conference! 

To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Liver Cancer

Kristie L. Kahl
The Food and Drug Administration approved Cabometyx (cabozantinib) tablets for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with Nexavar (sorafenib).
Beth Fand Incollingo
AN ANTIOXIDANT APPROVED FOR use as an antidote to cyanide poisoning may also prevent hearing loss, a potential side effect of the chemotherapy drug cisplatin, in children who take the anticancer drug.
Jason Harris
Immunotherapy pioneers James P. Allison, Ph.D., and Tasuku Honjo, M.D., Ph.D., have won the 2018 Nobel Prize in Physiology or Medicine for their research that eventually led to the use of immune checkpoint inhibitors to treat cancer.
Brielle Urciuoli
The Food and Drug Administration (FDA) approved Lenvima (lenvatinib) for the firstline treatment of patients with unresectable hepatocellular carcinoma (HCC).
Andrea J. Wilson
A liver cancer specialist can be very beneficial for those diagnosed.
Kristie L. Kahl
The Food and Drug Administration (FDA) granted a priority review to Keytruda (pembrolizumab) for the treatment of previously treated patients with advanced hepatocellular carcinoma (HCC).
After 10 years without a new drug for liver cancer, two approvals and a promising pipeline are changing the landscape.
Wayne Kuznar
Treatment with the PD-1 inhibitor Keytruda (pembrolizuumab) elicited promising progression-free survival (PFS) and overall survival (OS) results in patients with advanced hepatocellular carcinoma (HCC) who received previous treatment with Nexavar (sorafenib), according to phase 2 findings.
Silas Inman
“Patients with advanced hepatocellular carcinoma often have a poor prognosis and limited treatment options following prior systemic therapy,” lead investigator Ghassan K. Abou-Alfa, M.D.
Ghassan K. Abou-Alfa, MD, shares his excitement over the use of immunotherapy for liver cancer in 2018, and highlights research initiatives that are studying its potential in combination with other therapies.

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

Patient Caregiver Advocate Other